Affinity Asset Advisors Portfolio holdings
Affinity Asset Advisors runs private funds that go long and short on healthcare stocks. Its focus is pharmaceutical and biotechnology companies that develop drug therapies. Michael Cho and Jonathan Chu founded the firm, and Cho is its managing partner. Its funds may also hold investments in private companies, such as convertible debt and preferred equity.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VOGX
Vogenx Inc
VOGX
|
+$25.3M |
| 2 |
Arrowhead Research
ARWR
|
+$22.3M |
| 3 |
Alkermes
ALKS
|
+$21.4M |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$18.1M |
| 5 |
Tyra Biosciences
TYRA
|
+$17.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apogee Therapeutics
APGE
|
+$131M |
| 2 |
AnaptysBio
ANAB
|
+$43M |
| 3 |
Nuvalent
NUVL
|
+$34M |
| 4 |
Forte Biosciences
FBRX
|
+$24.3M |
| 5 |
Roivant Sciences
ROIV
|
+$19.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.31% |
| 2 | Miscellaneous | 30.5% |
| 3 | Financials | 1.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
enGene Therapeutics
ENGN
$162M
| – | – |
-600,000
| Closed | -$1.04M | – |
|
|
127
DELISTED
Forte Biosciences
FBRX
| – | – |
-1,145,391
| Closed | -$24.3M | – |
|
128
DELISTED
Karyopharm Therapeutics
KPTI
| – | – |
-312,500
| Closed | -$3.05M | – |
|
129
CALL
Eli Lilly
LLY
$1.29T
| – | – |
-20,000
| Closed | -$24M | – |
|
|
130
DELISTED
Nuvalent
NUVL
| – | – |
-275,000
| Closed | -$34M | – |
|
131
Orchestra BioMed
OBIO
$571M
| – | – |
-33,400
| Closed | -$144K | – |
|
132
PUT
Omeros
OMER
$1.27B
| – | – |
-1,411,300
| Closed | -$13.4M | – |
|
133
CALL
uniQure
QURE
$1.67B
| – | – |
-200,000
| Closed | -$9.21M | – |
|
|
134
uniQure
QURE
$1.67B
| – | – |
-175,000
| Closed | -$8.06M | – |
|
135
DELISTED
Rocket Pharmaceuticals Warrant
RCKTW
| – | – |
-75,000
| Closed | -$278 | – |
|
136
CALL
Summit Therapeutics
SMMT
$11.3B
| – | – |
-100,000
| Closed | -$1.46M | – |
|
137
Teva Pharmaceutical Industries Limited
TEVA
$51.9B
| – | – |
-374,000
| Closed | -$12.7M | – |
|
138
Boundless Bio
BOLD
$59M
| – | – |
-250,000
| Closed | -$625K | – |
|
139
OnKure Therapeutics
OKUR
$108M
| – | – |
-240,963
| Closed | -$1.1M | – |
|
140
Spruce Biosciences
SPRB
$124M
| – | – |
-30,000
| Closed | -$1.62M | – |
|
141
PUT
Evommune Inc
EVMN
$315M
| – | – |
-500,100
| Closed | -$6.65M | – |
|
142
SpyGlass Pharma
SGP
$1.1B
| – | – |
-131,586
| Closed | -$2.93M | – |
|
Similar funds
Affinity Asset Advisors's Q3 2026 Portfolio in Review
As of Q3 2026, Affinity Asset Advisors held 145 positions worth $2.46B, up 11% from $2.21B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Affinity Asset Advisors withdrew a net $115M in Q3 2026, closing 24 positions and reducing 29 holdings. Its most notable exit was Apogee Therapeutics, an estimated $131M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Affinity Asset Advisors opened a new position in Vogenx Inc worth $20.9M.
- Affinity Asset Advisors's largest Q3 2026 buy was Vogenx Inc: 915,000 shares worth $20.9M.
- Affinity Asset Advisors added most to Arrowhead Research in Q3 2026, an estimated $22.3M increase.
- Affinity Asset Advisors's biggest Q3 2026 reduction was AnaptysBio, cutting an estimated $43M.
- Affinity Asset Advisors fully exited Apogee Therapeutics in Q3 2026, selling an estimated $131M.
- Affinity Asset Advisors's ten largest holdings make up 42% of its $2.46B portfolio in Q3 2026.
- Affinity Asset Advisors opened 32 new positions and closed 24 in Q3 2026.
- Affinity Asset Advisors's portfolio value rose 11% quarter-over-quarter to $2.46B.
Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.